Your browser doesn't support javascript.
loading
Regulation of Tolerogenic Features on Dexamethasone-Modulated MPLA-Activated Dendritic Cells by MYC.
García-González, Paulina A; Maggi, Jaxaira; Schinnerling, Katina; Sepúlveda-Gutiérrez, Alejandro; Soto, Lilian; Neira, Oscar; Mehdi, Ahmed M; Nel, Hendrik J; Pesce, Bárbara; Aravena, Octavio; Molina, María Carmen; Catalán, Diego; Thomas, Ranjeny; Verdugo, Ricardo A; Aguillón, Juan Carlos.
Affiliation
  • García-González PA; Programa Disciplinario de Inmunología, Facultad de Medicina, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
  • Maggi J; Programa Disciplinario de Inmunología, Facultad de Medicina, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
  • Schinnerling K; Programa Disciplinario de Inmunología, Facultad de Medicina, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
  • Sepúlveda-Gutiérrez A; Programa de Genética Humana, ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
  • Soto L; Programa Disciplinario de Inmunología, Facultad de Medicina, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
  • Neira O; Unidad de Dolor, Departamento de Medicina, Hospital Clínico Universidad de Chile, Santiago, Chile.
  • Mehdi AM; Sección de Reumatología, Hospital del Salvador, Santiago, Chile.
  • Nel HJ; Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia.
  • Pesce B; Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia.
  • Aravena O; MED.UCHILE-FACS Laboratorio, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
  • Molina MC; Programa Disciplinario de Inmunología, Facultad de Medicina, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
  • Catalán D; Programa Disciplinario de Inmunología, Facultad de Medicina, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
  • Thomas R; Programa Disciplinario de Inmunología, Facultad de Medicina, Instituto de Ciencias Biomédicas, Universidad de Chile, Santiago, Chile.
  • Verdugo RA; Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia.
  • Aguillón JC; Programa de Genética Humana, ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Front Immunol ; 10: 1171, 2019.
Article in En | MEDLINE | ID: mdl-31191540
ABSTRACT
The potential of tolerogenic dendritic cells (tolDCs) to shape immune responses and restore tolerance has turn them into a promising therapeutic tool for cellular therapies directed toward immune regulation in autoimmunity. Although the cellular mechanisms by which these cells can exert their regulatory function are well-known, the mechanisms driving their differentiation and function are still poorly known, and the variety of stimuli and protocols applied to differentiate DCs toward a tolerogenic phenotype makes it even more complex to underpin the molecular features involved in their function. Through transcriptional profiling analysis of monocyte-derived tolDCs modulated with dexamethasone (Dex) and activated with monophosphoryl lipid A (MPLA), known as DM-DCs, we were able to identify MYC as one of the transcriptional regulators of several genes differentially expressed on DM-DCs compared to MPLA-matured DCs (M-DCs) and untreated/immature DCs (DCs) as revealed by Ingenuity Pathway Analysis (IPA) upstream regulators evaluation. Additionally, MYC was also amidst the most upregulated genes in DM-DCs, finding that was confirmed at a transcriptional as well as at a protein level. Blockade of transactivation of MYC target genes led to the downregulation of tolerance-related markers IDO1 and JAG1. MYC blockade also led to downregulation of PLZF and STAT3, transcription factors associated with immune regulation and inhibition of DC maturation, further supporting a role of MYC as an upstream regulator contributing to the regulatory phenotype of DM-DCs. On the other hand, we had previously shown that fatty acid oxidation, oxidative metabolism and zinc homeostasis are amongst the main biological functions represented in DM-DCs, and here we show that DM-DCs exhibit higher intracellular expression of ROS and Zinc compared to mature M-DCs and DCs. Taken together, these findings suggest that the regulatory profile of DM-DCs is partly shaped by the effect of the transcriptional regulation of tolerance-inducing genes by MYC and the modulation of oxidative metabolic processes and signaling mediators such as Zinc and ROS.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dendritic Cells / Dexamethasone / Gene Expression Regulation / Genes, myc / Gene Expression Profiling / Lipid A Type of study: Guideline / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Front Immunol Year: 2019 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dendritic Cells / Dexamethasone / Gene Expression Regulation / Genes, myc / Gene Expression Profiling / Lipid A Type of study: Guideline / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Front Immunol Year: 2019 Document type: Article Affiliation country: